Showing results (461-470 of 532) with videos related to
Sort By:
Pageof 54
American Journal of Hematology|February 18, 2017
Efficacy of the oral mTORC1 inhibitor everolimus in relapsed or refractory indolent lymphomaN Nora Bennani, Betsy R LaPlant, Stephen M Ansell, et al.Blood|December 18, 2012
Phase 1 study of pomalidomide MTD, safety, and efficacy in patients with refractory multiple myeloma who have received lenalidomide and bortezomibPaul G Richardson, David Siegel, Rachid Baz, et al.Biorxiv : the Preprint Server for Biology|August 14, 2023
Systematic characterization of therapeutic vulnerabilities in Multiple Myeloma with Amp1q reveals increased sensitivity to the combination of MCL1 and PI3K inhibitorsRomanos Sklavenitis-Pistofidis, Elizabeth D Lightbody, Mairead Reidy, et al.Blood Cancer Discovery|July 16, 2021
ROBO1 Promotes Homing, Dissemination, and Survival of Multiple Myeloma within the Bone Marrow MicroenvironmentGiada Bianchi, Peter G Czarnecki, Matthew Ho, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 30, 2009
Multicenter, phase I, dose-escalation trial of lenalidomide plus bortezomib for relapsed and relapsed/refractory multiple myelomaPaul G Richardson, Edie Weller, Sundar Jagannath, et al.Cancer|February 15, 2022
Quality of life, psychological distress, and prognostic perceptions in patients with multiple myelomaElizabeth K O'Donnell, Yael N Shapiro, Andrew J Yee, et al.Nature Chemical Biology|May 28, 2026
Pharmacological targeting of IRF4 as a therapeutic strategy for multiple myelomaMichael P Agius, Chen Song, Qi Liu, et al.Blood|March 13, 2008
Targeting NF-kappaB in Waldenstrom macroglobulinemiaXavier Leleu, Jérôme Eeckhoute, Xiaoying Jia, et al.Medrxiv : the Preprint Server for Health Sciences|May 3, 2024
Long-Term Follow-Up Defines the Population That Benefits from Early Interception in a High-Risk Smoldering Multiple Myeloma Clinical Trial Using the Combination of Ixazomib, Lenalidomide, and DexamethasoneOmar Nadeem, Michelle P Aranha, Robert Redd, et al.Nature Reviews. Cancer|October 1, 2024
Defining precancer: a grand challenge for the cancer communityJessica Faupel-Badger, Indu Kohaar, Manisha Bahl, et al.Pageof 54